이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients

2026년 7월 11일 업데이트: Dr Lingaraj Nayak, Tata Memorial Centre

Use of Leflunomide as Primary Prophylaxis Against Cytomegalovirus (CMV) Reactivation in Haploidentical Haematopoietic Stem Cell Transplant (HIT) - Single, Arm, Phase 2 Clinical Trial

Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety.

The main questions it aims to answer are -

  1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage?
  2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml?
  3. Does leflunomide prevent the need to start pre-emptive therapy for cytomegalovirus (CMV)?
  4. Is it safe to use in bone marrow transplant ( BMT) patients?
  5. Does leflunomide prevent other viral reactivations - like Adeno virus and BK virus?
  6. Does leflunomide affect the risk of acute graft-versus-host disease ( acute GVHD) after bone marrow transplant (BMT)?

What medicine will the patients receive? Patients in study shall receive loading dose of Tab. Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day +180 post transplant or till patient is on immunosuppressant medicines.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Introduction :While pre-emptive medications have lowered the frequency of cytomegalovirus (CMV) illness after HSCT, CMV reactivation remains associated with higher mortality. Haploidentical transplant (haplo-HSCT) are high risk transplants, which have increased risk of viral reactivations. Current antiviral treatments, such as ganciclovir, have serious adverse effects and are limited in their use, whereas letermovir is expensive and unavailable in India.

Leflunomide, a medicine, which is used in Rheumatoid arthritis, is a possible alternative due to its antiviral effects and low cost. It may be beneficial at preventing cytomegalovirus (CMV) reactivation, particularly in patients with low viral levels. Furthermore, leflunomide has demonstrated efficacy against BK virus and other DNA viruses, making it a possible multifaceted preventive treatment for high-risk haplo-identical hematopoietic stem cell transplantation (HSCT) recipients.

Hypothesis Leflunomide is effective in decreasing clinically significant CMV(cytomegalovirus) infection after haplo-hematopoietic stem cell transplantation (HSCT)

Target population Patients ≥18 years of age who are undergoing haplo-hematopoietic stem cell transplantation (HSCT) for any malignancy at Tata Memorial centre ACTREC, Mumbai

Aims:

To evaluate efficacy of leflunomide as a prophylactic agent against cytomegalovirus (CMV)reactivation in Haplo-hematopoietic stem cell transplantation (HSCT).

Objectives -

Primary objective To determine the rate of clinically significant CMV infection on prophylactic leflunomide in haplo-HSCT patients till day+180 post HSCT

Secondary objective

  1. To evaluate the safety of post-transplant leflunomide using CTCAE 5.0 grading.
  2. To evaluate the incidence of clinically significant BK virus reactivation in peripheral blood and urine till day+180. Clinically significant BK virus reactivation will be defined as per ECIL-6 guidelines as more than 10^7 copies (7 log10 gEq/mL) in urine and 10^3 copies (1000 gEq/mL) in blood will be considered significant thresholds to define BK virus re- activation
  3. To evaluate the incidence of grade III - IV acute GVHD.

Study schema - Single-arm, Phase 2, prospective, interventional study

Administration of study treatment Once neutrophil engraftment has occurred i.e., ANC≥500/mm (on or before day-28), all patients in study shall receive loading dose of Tab. Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day +180 post haplo-HSCT or till patient is on systemic immunosuppression

Timing of dose administration Study therapy should be administered/taken at the same time each day. Tablets are to be swallowed whole (i.e., no crushing or chewing the tablet is allowed). Study therapy may be administered with or without food. If a subject misses a dose, the missed dose should be given as soon as possible during the same day. If more than 18 hours have gone by after the regular dosing time, then the missed dose should be skipped and the normal dosing schedule should be resumed. The next dose should not be doubled in order to "make up" what has been missed.

Investigations During Treatment Monitoring: Weekly cytomegalovirus (CMV) PCR in blood, bi-weekly BK virus PCR in blood and urine, and additional tests as clinically indicated.

Overall study duration - 5 years

연구 유형

중재적

등록 (추정된)

22

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

  • 인도
    • Maharashtra
      • Navi Mumbai, Maharashtra, 인도, 410210
        • 모병
        • Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Lingaraj Nayak, MD, DM
        • 부수사관:
          • Sumeet Mirgh, MD, DM
      • Navi Mumbai, Maharashtra, 인도, 410210
        • 아직 모집하지 않음
        • Advanced Centre for Treatment, Research and Education in Cancer
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Dr Lingaraj Nayak, MBBS MD DM Medical Oncology

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Males or females undergoing Haplo-identical haematopoetic stem cell transplant.
  2. Age ≥18yrs on the day of signing informed consent
  3. Undetectable CMV from plasma sample in preceding 7 days
  4. Patient who has WBC engraftment (ANC>=500/cumm for 3 or more consecutive days).
  5. Within 7 days of WBC engraftment
  6. Adequate liver functions (ALT / AST less than 5 times upper limit of normal and Bilirubin <=3 times upper limit of normal) at time of starting leflunomide
  7. Understands the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agree to participate by giving written informed consent.

Exclusion Criteria:

  1. Known hypersensitivity to Leflunomide
  2. History of clinically significant CMV reactivation in past 1 year
  3. Patient is receiving/has received drug known to have anti CMV activity within in last 7 days [Ganciclovir, valganciclovir, foscarnet, letermovir, acyclovir (at doses >=3200 mg PO per day or >=25 mg/kg IV per day), valacyclovir (at doses &>=3000 mg PO per day)]
  4. Inadequate renal function (creatinine clearance <=30 ml/min)
  5. Chronic active hepatitis B (HBsAg+ or any HBV DNA+), hepatitis C, or/and HIV
  6. Any psychiatric condition that might limit the ability of the patient to comply with the protocol

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Leflunomide
This will be a single arm open label intervention study. Patients who undergo haploidentical transplant, within 7 days of engraftment, will receive leflunomide till day+180 post transplant or till patient is on systemic immunosuppression.
의약품: Leflunomide 20 mg
Patients in study shall receive loading dose of Tab Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day 180 + post haploidentical transplant or till patient is on systemic immunosuppression.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of participants with clinically significant cytomegalovirus (CMV) infection
기간: Through Day +180 post hematopoietic stem cell transplantation (HSCT).

Number of participants with clinically significant cytomegalovirus (CMV) infection through Day +180 after hematopoietic stem cell transplantation (HSCT). Clinically significant CMV infection is defined as the occurrence of one or more of the following:

Cytomegalovirus (CMV) end-organ disease; Cytomegalovirus (CMV) viremia ≥2,000 copies/mL measured by the central laboratory; or Initiation of pre-emptive anti-CMV therapy at the investigator's discretion.
Through Day +180 post hematopoietic stem cell transplantation (HSCT).

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants with treatment-emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
기간: Day+180 post transplant
Number of participants experiencing treatment-emergent adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Day+180 post transplant
Number of participants with clinically significant BK virus reactivation
기간: Day+180 post transplant

Number of participants with clinically significant BK virus reactivation through Day +180 after hematopoietic stem cell transplantation. Clinically significant BK virus reactivation is defined according to European Conference on Infections in Leukaemia (ECIL)-6 criteria as:

Urine BK viral load >10⁷ copies/mL (>7 log₁₀ genome equivalents/mL), or Blood BK viral load >10³ copies/mL (>1,000 genome equivalents/mL).
Day+180 post transplant
Number of participants with Grade III-IV acute graft-versus-host disease
기간: Day+180 post transplant
Number of participants who develop Grade III-IV acute graft-versus-host disease (aGVHD) according to the study-defined grading criteria.
Day+180 post transplant

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Tata Memorial Centre

협력자

Indian Council of Medical Research

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 10월 18일

기본 완료 (추정된)

2029년 4월 1일

연구 완료 (추정된)

2029년 4월 1일

연구 등록 날짜

최초 제출

2025년 1월 25일

QC 기준을 충족하는 최초 제출

2026년 7월 11일

처음 게시됨 (실제)

2026년 7월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 11일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 901006

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

At this time, we do not plan to share individual participant data (IPD) due to concerns regarding patient privacy, the regulatory requirements for data sharing for maintaining patient confidentiality

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

혈액 악성종양에 대한 임상 시험

Leflunomide 20 mg에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Canada

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다